Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) EBT (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of EBT data on record, last reported at -$81.3 million in Q4 2025.

  • For Q4 2025, EBT fell 72.68% year-over-year to -$81.3 million; the TTM value through Dec 2025 reached -$258.8 million, down 63.91%, while the annual FY2025 figure was -$258.8 million, 63.91% down from the prior year.
  • EBT reached -$81.3 million in Q4 2025 per CLDX's latest filing, down from -$67.0 million in the prior quarter.
  • Across five years, EBT topped out at -$13.4 million in Q2 2021 and bottomed at -$81.3 million in Q4 2025.
  • Average EBT over 5 years is -$37.1 million, with a median of -$34.3 million recorded in 2024.
  • Peak YoY movement for EBT: plummeted 169.23% in 2022, then increased 15.28% in 2023.
  • A 5-year view of EBT shows it stood at -$20.1 million in 2021, then crashed by 31.46% to -$26.5 million in 2022, then plummeted by 63.5% to -$43.3 million in 2023, then decreased by 8.74% to -$47.1 million in 2024, then plummeted by 72.68% to -$81.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$81.3 million in Q4 2025, -$67.0 million in Q3 2025, and -$56.6 million in Q2 2025.